Alkem Labs, a leading Indian drug maker, is set for a top management change. Vikas Gupta, the CEO for nearly three years, is expected to de...

Mounjaro, the star pharmaceutical from Eli Lilly, is experiencing a downturn in sales across India. This slump can be attributed to competi...

Drug maker Cipla has acquired Inzpera Healthscience for approximately Rs 111 crore. This strategic move combines Inzpera's paediatric produ...

Observations are largely related to procedure and SOP lapses, Equirius said.

In a foes-turn-friends move announced on February 27, the Mumbai-based drug maker announced that it will partner Swiss biotech company Roch...

Roche said this partnership will also enable it to focus on bringing new, transformative medicines to patients in India.

Alkem is bringing in a fresh brand. Evogliptin has been approved in South Korea and the company is waiting for an approval from the USFDA a...

The court said it can't make a definitive conclusion that Novartis' imports of Onbrez were insufficient to meet the demands COPD patients f...

According to the judgment, Cipla had claimed that 10 tablets of Onbrez cost Rs 677 as opposed to its own drug priced at Rs 130.

Cipla had based its application to the panel on the bioequivalence studies with Exubra, an inhalation drug and device combination that was ...

Chase was recently financed by a Series B consortium consisting of New Rhein Healthcare, Edmond de Rothschild Investment Partners and Cipla...

Cipla has stepped up launch plans in areas like respiratory, dermatology, cardiovascular and urology, which will help speed up its India gr...

The authority has charged Cipla of charging higher prices for a set of drugs than the ceiling price based on a fixed formula.

The deal closure, that involved approvals from the US regulatory agencies, will see Cipla vault its sales from that market to around $400 m...

Cipla said it could take a decision to buy stake of up to 25 per cent in South Africa-based, Cipla Medpro in next board meeting. Cipla Medp...

Drug maker Cipla on Tuesday said it will invest USD 65 million (nearly Rs 300 crore) over the next three years with a Chinese joint venture...

The Delhi HC rejected an injunction plea by Swiss drug major Roche to prevent Cipla from manufacturing generic versions of anti-cancer drug...